KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Leases (2019 - 2025)

Historic Capital Leases for Aurinia Pharmaceuticals (AUPH) over the last 3 years, with Q3 2025 value amounting to $55.7 million.

  • Aurinia Pharmaceuticals' Capital Leases fell 1550.75% to $55.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 1550.75%. This contributed to the annual value of $58.6 million for FY2024, which is 2242.35% down from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Capital Leases stood at $55.7 million, which was down 1550.75% from $59.3 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Capital Leases' 5-year high stood at $79.4 million during Q2 2023, with a 5-year trough of $55.7 million in Q3 2025.
  • Moreover, its 3-year median value for Capital Leases was $65.4 million (2024), whereas its average is $65.6 million.
  • Examining YoY changes over the last 5 years, Aurinia Pharmaceuticals' Capital Leases showed a top increase of 864.07% in 2024 and a maximum decrease of 2242.35% in 2024.
  • Aurinia Pharmaceuticals' Capital Leases (Quarter) stood at $75.5 million in 2023, then dropped by 22.42% to $58.6 million in 2024, then decreased by 4.83% to $55.7 million in 2025.
  • Its Capital Leases was $55.7 million in Q3 2025, compared to $59.3 million in Q2 2025 and $56.8 million in Q1 2025.